RAC Stock Overview
Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Race Oncology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.39 |
| 52 Week High | AU$1.99 |
| 52 Week Low | AU$0.64 |
| Beta | 1.5 |
| 1 Month Change | -8.55% |
| 3 Month Change | 71.60% |
| 1 Year Change | -27.03% |
| 3 Year Change | -57.23% |
| 5 Year Change | 2,038.46% |
| Change since IPO | 424.53% |
Recent News & Updates
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate
Jan 23
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 05Recent updates
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate
Jan 23Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 05Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth
Jun 20We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow
Feb 17Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation
Oct 14Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation
Apr 01We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely
Apr 05What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?
Mar 01How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?
Jan 07
Shareholder Returns
| RAC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -9.7% | -3.8% | -3.1% |
| 1Y | -27.0% | -8.7% | 4.0% |
Return vs Industry: RAC underperformed the Australian Biotechs industry which returned -8.7% over the past year.
Return vs Market: RAC underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| RAC volatility | |
|---|---|
| RAC Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RAC's share price has been volatile over the past 3 months.
Volatility Over Time: RAC's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.raceoncology.com |
Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection.
Race Oncology Limited Fundamentals Summary
| RAC fundamental statistics | |
|---|---|
| Market cap | AU$229.59m |
| Earnings (TTM) | -AU$11.17m |
| Revenue (TTM) | AU$5.82m |
39.6x
P/S Ratio-20.6x
P/E RatioIs RAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAC income statement (TTM) | |
|---|---|
| Revenue | AU$5.82m |
| Cost of Revenue | AU$2.87m |
| Gross Profit | AU$2.95m |
| Other Expenses | AU$14.13m |
| Earnings | -AU$11.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.067 |
| Gross Margin | 50.73% |
| Net Profit Margin | -192.14% |
| Debt/Equity Ratio | 0% |
How did RAC perform over the long term?
See historical performance and comparison